Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age

Size: px
Start display at page:

Download "Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age"

Transcription

1 Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age Components of Severity Symptoms Intermittent 2 days/week Classification of Asthma Severity (0 4 years of age) Persistent Mild Moderate Severe > 2 days/week but not daily Daily Throughout the day Impairment Risk Nighttime awakenings 0 1 2x/month 3 4x/month >1x/week Short acting beta 2 agonist use for symptom control (not prevention of EIB) Interference with normal activity Exacerbations requiring oral systemic corticosteroids 2 days/week > 2 days/week but not daily Daily Several times per day None Minor limitation Some limitation Extremely limited 0 1/year 2 exacerbations in 6 months requiring oral systemic corticosteroids, or 4 wheezing episodes/1 year lasting > 1 day AND risk factors for persistent asthma Consider severity and interval since last exacerbation Frequency and severity may fluctuate t over time Exacerbations of any severity may occur in patients in any severity category Recommended Step for Initiating Treatment Step 1 Step 2 Step 3 and consider short course of oral systemic corticosteroids In2 6 weeks, dependingon severity, evaluate level of asthma control that is achieved. If no clear benefit is observed in 4 6 weeks, consider adjusting therapy or alternative diagnosis EIB = exercise induced bronchospasm National Asthma Education and Prevention Program. Publication No Available from:

2 Classifying Asthma Severity and Initiating Treatment in Children 5 11 Years of Age Components of Severity Intermittent Classification of Asthma Severity (5 11 years of age) Persistent Mild Moderate Severe Symptoms 2 days/week > 2 days/week kbut not daily dil Dil Daily Throughout h the day Impairment Nighttime awakenings 2x/month 3 4x/month > 1x/week but not nightly Often 7x/week Short acting beta 2 agonist use for symptom control 2 days/week > 2 days/weekbut not daily Daily Several times per day (not prevention of EIB) Interference with normal activity None Minor limitation Some limitation Extremely limited Lung function Normal FEV 1 between exacerbations FEV 1 > 80% predicted FEV 1 /FVC >85% FEV 1 = >80% predicted FEV 1 /FVC >80% FEV 1 = 60 80% predicted FEV 1 /FVC =75 80% FEV 1 < 60% predicted FEV 1 /FVC <75% Risk 0 1/year 2/year Exacerbations requiring oral systemic corticosteroids Consider severity and interval since last exacerbation Frequency and severity may fluctuate over time for patients in any severity category Recommended Step for Initiating Treatment Relative annual risk of exacerbations may be related to FEV 1 Step 3, medium dose ICS option Step 1 Step 2 Step 3, medium dose ICS option, or Step 4 and consider short course of oral systemic corticosteroids In 2 6 weeks, evaluate level of asthma control that is achieved, and adjust therapy accordingly FEV 1 = forced expiratory volume in 1 second; FVC = forced vital capacity; ICS = inhaled corticosteroids National Asthma Education and Prevention Program. Publication No Available from:

3 FDA Approved Agents in Children ICS Age indications Mometasone 110 mcg ages 4 to 11, 220 mcg down to age 12 Budesonide MDI down to age 6, respules down to age 12 months to 8 years Fluticasone MDI and Diskus down to age 4 Beclomethasone Down to age 5 Ciclesonide Down to age 12 ICS + LABA Age Indication Fluticasone/salmeterol MDI down to age 12 years, Diskus down to age 4 years Budesonide/formoterol MDI down to age 12 years Mometasone/formoterol MDI down to age 12 years LABA = long acting beta agonist; MDI = meter dose inhaler National Asthma Education and Prevention Program. Publication No Available from:

4 FDA Approved LTRA Agents in Adults Leukotriene Receptor Antagonists Doses Zafirlukast 10 mg twice daily ages 5 11 Montelukast 4 mg oral granules ages 6 23 months, 4 mg oral granules or oral tablet ages 2 5, 5 mg chewable tablet ages 6 14 LTRA L k t i R t At it LTRA = Leukotriene Receptor Antagonists National Asthma Education and Prevention Program. Publication No Available from:

5 Stepwise Approach for Managing Asthma in Children 0 4 Years of Age Intermittent Asthma Step 1 short acting beta2 agonist (SABA) As needed Step 2 Low dose ICS Cromolyn or Montelukast Persistent Asthma: Daily Medication Consult with asthma specialist if step 3 care or higher is required. Consider consultation at step 2. Step 3 Mediumdose ICS Step 4 Mediumdose ICS + either LABA or Montelukast Step 5 High dose ICS + either LABA or Montelukast Patient Education and Environmental Control at Each Step Step 6 High dose ICS + either LABA or Montelukast Oral systemic Corticosteroids Quick Relief Medication for All Patients SABA as needed for symptoms. Intensity of treatment depends on severity of symptoms. With viral respiratory infection: SABA q 4 6 hours up to 24 hours (longer with physician consult). Consider short course of oral systemic corticosteroids if exacerbation is severe or patient has history of previous severe exacerbations. Caution: Frequent use of SABA may indicate the need to step up treatment. See text for recommendations on initiating daily long term control therapy. Alphabetical order is used when more than one treatment option is listed within either preferred or alternative therapy. National Asthma Education and Prevention Program. Publication No Available from: Step up if needed (first, check adherence, inhaler technique, and environmental control) Assess control Step down if possible (and asthma is well controlled at least 3 months)

6 Stepwise Approach for Managing Asthma in Children 5 11 Years of Age Intermittent Asthma Step 1 Step2 Low dose ICS SABA Cromolyn, As needed LTRA, Nedocromil, or Theophylline Persistent Asthma: Daily Medication Consult with asthma specialist if step 4 care or higher is required. Consider consultation at step 3. Step 3 EITHER: Low dose ICS + either LABA, LTRA, or Theohylline OR medium dose ICS Step 4 Medium dose ICS + LABA Medium dose ICS+ either LTRA or Theophylline Step 5 High dose ICS + LABA High dose ICS + either LTRA or Theophylline Step 6 High dose ICS + LABA + oral systemic corticosteroid High dose ICS + either LTRA or Theophylline + oral systemic corticosteroid Each step: Patient education, environmental control, and management of comorbidities. Steps 2 4: Consider subcutaneous allergen immunotherapy for patients who have allergic asthma* Quick Relief Medication for All Patients SABA as needed for symptoms. Intensity of treatment depends on severity of symptoms: up to 3 treatments at 20 minute intervals as needed. Short course of oral systemic corticosteroids may be needed Caution: Increasing use of SABA or use > 2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control and the need to step up treatment. Step up if needed (first, check adherence, inhaler technique, and environmental control, and comorbid conditions) Assess control Step down if possible (and asthma is well controlled at least 3 months) Alphabetical order is used when more than one treatment option is listed within either preferred or alternative therapy. National Asthma Education and Prevention Program. Publication No Available from:

7 Assessing Asthma Control and Adjusting Therapy in Children 0 4 Years of Age Components of Control Classification of Asthma Control (0 4 years of age) Well Controlled Not Well Controlled Very Poorly Controlled Symptoms 2 days/week > 2 days/week Throughout the day Nighttime awakenings 1x/month > 1x/month >1x/week Impairment Risk Interference with normal activity Short acting beta 2 agonist use for symptom control (not prevention of EIB) Exacerbations requiring oral systemic corticosteroids Treatment related adverse effects None Some limitation Extremely limited 2 days/week > 2 days/week Several times per day 0 1/year 2 3/year > 3/year Medication side effects can very in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk. Recommended Action for Treatment Maintain current treatment Regular follow up every 1 6 months Consider step down if well controlled for at least 3 months Step up (1 step) and Reevaluate in 2 6 weeks If no clear benefit in 4 6 weeks, consider alternative diagnoses or adjusting therapy For side effects, consider alternative ate at eteat treatment e t options Consider short course of oral systemiccorticosteroids ti t id Step up (1 2 steps), and Reevaluate in 2 weeks If no clear benefit in 4 6 weeks, consider alternative diagnoses or adjusting therapy For sdee side effects, ects,consider alternative treatment options National Asthma Education and Prevention Program. Publication No Available from:

8 Assessing Asthma Control and Adjusting Therapy in Children 5 11 Years of Age Components of Control Classification of Asthma Control (5 11 years of age) Well Controlled Not Well Controlled Very Poorly Controlled Symptoms 2 days/week but not more than once on each day > 2 days/week or multiple times on 2 days/month Throughout the day Nighttime awakenings 1x/month 2x/month > 2x/week Impairment Interference with normal activity None Some limitation Extremely limited Short acting beta 2 agonist use for symptom control (not 2 days/week 2 days/week Several times per day prevention of EIB) Lung function FEV 1 or peak flow FEV 1 /FVC > 80% predicted/personal best > 80% 60 80% predicted/personal best 75 80% < 60% predicted/personal best < 75% Risk Exacerbations requiring ii oral 0 1/year 2/year systemic corticosteroids Consider severity and interval since last exacerbation Reduction in lung growth Evaluation requires long term follow up Medication side effects can vary in intensity from none to very troublesome and worrisome. The level Treatment related adverse of intensity does not correlate to specific levels of control but should be considered in the overall effects ects assessment of risk ik Recommended Action for Treatment Maintain current step Regular follow up every 1 6 months Consider step down if well controlled for at least 3 months Step up at least 1 step and Reevaluate in 2 6 weeks For side effects, consider alternative treatment options Consider short course of oral systemic corticosteroids Step up 1 2 steps, and Reevaluate in 2 weeks Forside effects, consider alternative treatment options National Asthma Education and Prevention Program. Publication No Available from:

9 Classifying Asthma Severity and Initiating Treatment in Persons 12 Years of Age Impairment Components of Severity Symptoms Intermittent 2 days/week Classification of Asthma Severity ( 12 years of age) Persistent Mild Moderate Severe > 2 days/week but not daily Nighttime awakenings 2x/month 3 4x/month Daily > 1x/week but not nightly Throughout the day Often 7x/week Normal Short acting beta agonist use > 2 days/week 2 g 2 days/week FEV 1 /FVC: for symptom control (not but not daily, and not Daily Several times per day 8 19 yr: 85% prevention of EIB) more than 1x on any day yr: 80% Interference with normal activity None Minor limitation Some limitation Extremely limited yr: 75% Normal FEV 1 between FEV 1 > 60% but yr: 70% exacerbations FEV 1 > 80% predicted < 80% predicted FEV 1 < 60% predicted Lung function FEV 1 > 80% predicted FEV 1 /FVC normal FEV 1 /FVC reduced FEV 1 /FVC reduced > 5% FEV 1 /FVC normal 5% Risk Exacerbations requiring oral systemic corticosteroids 0 1/year 2/year Consider severity and interval since last exacerbation Frequency and severity may fluctuate over time for patients in any severity category Relative annual risk of exacerbations may be related to FEV 1 Recommended Step for Initiating Treatment Step 1 Step 2 Step 3 Step 4 or 5 and consider short course of oral systemic corticosteroids In 2 6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly National Asthma Education and Prevention Program. Publication No Available at:

10 Stepwise Approach for Managing Asthma in Youths 12 Years of Age and Adults Intermittent Asthma Step 1 SABA As needed Persistent Asthma: Daily Medication Consult with asthma specialist if step 4 care or higher is required. Consider consultation at step 3. Step2 Low dose ICS Cromolyn, LTRA, Nedocromil, or Theophylline Step 3 Low dose ICS + LABA OR mediumdose ICS low dose ICS + either LTRA, Theophylline, or Zileuton Step 4 Medium dose ICS + LABA Mediumdose ICS+either LTRA, Theophylline, or Zileuton Step 5 High dose ICS + LABA AND Consider Omalizumab for patients who have allergies Step 6 High dose ICS + LABA + oral corticosteroid AND Consider Omalizumab for patients who have allergies Each step: Patient education, environmental control, and management of comorbidities. Steps 2 4: Consider subcutaneous allergen immunotherapy for patients who have allergic asthma Quick Relief Medication for All Patients SABA as needed for symptoms. Intensity of treatment depends on severity of symptoms: up to 3 treatments at 20 minute intervals as needed. Short course of oral systemic corticosteroids may be needed Caution: Increasing use of SABA or use > 2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control and the need to step up treatment. Step up if needed (first, check adherence, environmental control, and comorbid conditions) Assess control Step down if possible (and asthma is well controlled at least 3 months) National Asthma Education and Prevention Program. Publication No Available from:

11 Assessing Asthma Control and Adjusting Therapy in Youth 12 Years of Age and Adults Components of Control Classification of Asthma Control ( 12 years ofage) Well Controlled Not Well Controlled Very Poorly Controlled Symptoms 2 days/week >2 days/week Throughout the day Nighttime awakenings 2x/month 1 3x/week 4x/week Interference with normal activity it None Some limitation Extremely limited Impairment Short acting beta 2 agonist use for symptom control (not prevention of EIB) FEV 1 or peak flow Validated Questionnaires ATAQ ACQ ACT Exacerbations requiring oral systemic corticosteroids 2 days/week >2 days/week Several times per day > 80% predicted/ personal best * % predicted/ personal best /year 2/year Consider severity and interval since last exacerbation < 60% predicted/ personal best 3 4 N/A 15 Risk Progressive loss of lung function Treatment related adverse effects Recommended Action for Treatment Evaluation requires long term follow up care Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk Maintain current step Regular follow ups every 1 6 months to maintain control Consider step down if well controlled for at least 3 months Step up 1 step and Reevaluate in 2 6 weeks Forside effects, consider alternative treatment options National Asthma Education and Prevention Program. Publication No Available from: Consider short course of oral systemic corticosteroids, Step up 1 2 steps, and Reevaluate in 2 weeks For side effects, consider alternative treatment options

12 FDA Approved ICS and Combination Agents in Adults ICS Mometasone Budesonide Doses Twisthaler 110 mcg or 220 mcg Flexhaler 90 mcg or 180 mcg Respules 0.25 & 0.5 mg or 1mg/2mL Fluticasone Diskus 50 mcg, 100 mcg or 250 mcg MDI 110 mcg or 220 mcg Beclomethasone MDI 40 mcg or 80 mcg Ciclesonide ICS + LABA MDI 80 mcg or 160 mcg Doses Fluticasone/salmeterol MDI 45/21, 115/21, 230/21 Diskus 100/50, 250/50 or 500/50 Budesonide/formoterol MDI 80/4.5 or 160/4.5 Mometasone/formoterol MDI 100/5 or 200/5 National Asthma Education and Prevention Program. Publication No Available from:

13 FDA Approved LTRA Agents in Adults Leukotriene Receptor Antagonists Zafirlukast Montelukast Doses 20 mg tablets 10 mg tablets National Asthma Education and Prevention Program. Publication No Available from:

It s all about asthma control

It s all about asthma control 2007 * National Heart, Lung, and Blood Institute/National Asthma Education and Prevention Program. It s all about asthma control New Guidelines, New Treatment Approach Brought to you by New Guidelines,

More information

2007 NIH Asthma Guidelines Summary

2007 NIH Asthma Guidelines Summary 2007 NIH Asthma Guidelines Summary Summary of the Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma National Institutes of Health (NIH) National Heart, Lung, and Blood Institute

More information

Persistent Asthma: Daily Medication. Consult with asthma specialist if step 3 care or higher is required. Consider consultation at step 2.

Persistent Asthma: Daily Medication. Consult with asthma specialist if step 3 care or higher is required. Consider consultation at step 2. Section 4, Managing Asthma Long Term in Children 0 4 Years of Age and 5 11 Years of Age FIGURE 4 1a. STEPWISE APPROACH FOR MANAGING ASTHMA IN CHILDREN 0 4 YEARS OF AGE Asthma Persistent Asthma: Medication

More information

2007 NIH Asthma Guidelines Summary

2007 NIH Asthma Guidelines Summary 2007 NIH Asthma Guidelines Summary Summary of the Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma National Institutes of Health (NIH) National Heart, Lung, and Blood Institute

More information

Managing Asthma Long Term

Managing Asthma Long Term Managing Asthma Long Term TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion KNOWLEDGE COMPONENTS DEFINITIONS RECOMMENDATION: F I G U R E 4 2 a. CLASSIFYING ASTHMA SEVERITY AND INITIATING

More information

Addressing Asthma Severity and Control

Addressing Asthma Severity and Control Asthma Diagnosis and Management Addressing Asthma Severity and Control Recommendations from the National Institutes of Health (NIH) Guidelines (NAEPP* Expert Panel Report 3: Guidelines for the Diagnosis

More information

Managing Asthma Long Term

Managing Asthma Long Term Managing Asthma Long Term TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS F I G U R E 4 2 a. CLASSIFYING ASTHMA SEVERITY AND INITIATING TREATME N T IN CHILDREN 0 4

More information

Learning the Asthma Guidelines by Case Studies. Timothy Craig, DO Professor of Medicine and Pediatrics Penn State University Hershey Medical Center

Learning the Asthma Guidelines by Case Studies. Timothy Craig, DO Professor of Medicine and Pediatrics Penn State University Hershey Medical Center Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Penn State University Hershey Medical Center Objectives 1. Learn the Asthma Guidelines 2. Be able to

More information

Learning the Asthma Guidelines by Case Studies

Learning the Asthma Guidelines by Case Studies Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma

More information

Before prescribing montelukast sodium, please read the accompanying Prescribing Information.

Before prescribing montelukast sodium, please read the accompanying Prescribing Information. Merck & Co., Inc. U.S. Human Health P.O. Box 1000 North Wales, PA 19454-1099 Dear Health Care Professional: Thank you for your interest in the enclosed attachment, Stepwise Approach for Managing, excerpted

More information

Ambulatory Asthma Management

Ambulatory Asthma Management Ambulatory Asthma Management Summary of Recommendations Algorithm Patient presents with symptoms of asthma Establish diagnosis and determine level of severity by H and P and spirometry. (A) Consider alternative

More information

ASTHMA PRACTICE GUIDELINE

ASTHMA PRACTICE GUIDELINE ASTHMA PRACTICE GUIDELINE Risk Intervention Goals Recommendations Reduce Impairment Prevent chronic troublesome symptoms. Require infrequent use of inhaled short-acting beta 2 agonist. Maintain (near)

More information

Implementing Guideline Based Strategies to Improve Adherence in Asthma Patients

Implementing Guideline Based Strategies to Improve Adherence in Asthma Patients Implementing Guideline Based Strategies to Improve Adherence in Asthma Patients Robert Sussman, MD Atlantic Health System Overlook Medical Center Asthma Remains a Serious Health Risk in the US Every day

More information

Asthma Action Plan. The goal of asthma treatment is to live a healthy, active life.

Asthma Action Plan. The goal of asthma treatment is to live a healthy, active life. Name of Birth Effective s Mild Intermittent Moderate Mild Severe control medicines required. PATIENT COPY Name of Student: DISTRICT OF COLUMBIA DEPARTMENT OF HEALTH SCHOOL HEALTH PROGRAM STUDENT HEALTH

More information

Key Components in Treating Asthma in Adults and Children Older than 5 Years: Diagnosis, Treatment and Referral

Key Components in Treating Asthma in Adults and Children Older than 5 Years: Diagnosis, Treatment and Referral Key Components in Treating Asthma in Adults and Children Older than 5 Years: Diagnosis, Treatment and Referral Initial Asthma Assessment Critical to accurately diagnose asthma by: Identifying the presence

More information

Philip Marcus, MD MPH FCCP FACP Chief, Division of Pulmonary Medicine St. Francis Hospital-Roslyn NY Associate Dean, Curriculum Development New York

Philip Marcus, MD MPH FCCP FACP Chief, Division of Pulmonary Medicine St. Francis Hospital-Roslyn NY Associate Dean, Curriculum Development New York Philip Marcus, MD MPH FCCP FACP Chief, Division of Pulmonary Medicine St. Francis Hospital-Roslyn NY Associate Dean, Curriculum Development New York College of Osteopathic Medicine Asthma prevalence: 20.5

More information

Figure 1. SUMMARY OF RECOMMENDED KEY CLINICAL ACTIVITIES FOR THE DIAGNOSIS AND MANAGEMENT OF ASTHMA

Figure 1. SUMMARY OF RECOMMENDED KEY CLINICAL ACTIVITIES FOR THE DIAGNOSIS AND MANAGEMENT OF ASTHMA Figure 1. SUMMARY OF RECOMMENDED KEY CLINICAL ACTIVITIES FOR THE DIAGNOSIS AND MANAGEMENT OF ASTHMA DIAGNOSIS Establish asthma diagnosis. Use medical history and physical examination to determine that

More information

Diagnosis, Evaluation and Management of Adults and Children with Asthma

Diagnosis, Evaluation and Management of Adults and Children with Asthma Clinical Guideline for the Diagnosis, Evaluation and Management of Adults and Children with Asthma Color Key n Four Components of Asthma Care n Classifying Asthma Severity, Assessing Asthma Control and

More information

National Institutes of Health (NIH) NAEPP 2007 Asthma Guideline Expert Panel Report (EPR) 3

National Institutes of Health (NIH) NAEPP 2007 Asthma Guideline Expert Panel Report (EPR) 3 National Institutes of Health (NIH) NAEPP 2007 Asthma Guideline Expert Panel Report (EPR) 3 Susan K. Ross RN, AE C MDH Asthma Program 651 201 201 5629 Susan.Ross@state.mn.us 1 National Institutes of Health

More information

Monitoring written action plans compared to medical management alone, and peak flow-based compared to symptom-based written action plans

Monitoring written action plans compared to medical management alone, and peak flow-based compared to symptom-based written action plans National Asthma Education and Prevention Program Q U I C K R E F E R E N C E NAEPP Expert Panel Report Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics 2002* The National

More information

Dear Provider: Sincerely,

Dear Provider: Sincerely, Asthma Toolkit Dear Provider: L.A. Care is pleased to present this updated asthma toolkit. Our goal is to promote the highest level of asthma care, based on the 2007 National Asthma Education and Prevention

More information

Module 4. Special Populations. Geneva Briggs

Module 4. Special Populations. Geneva Briggs Module 4 Special Populations Geneva Briggs Pre-Assessment Exercise 1 Question #1 Which medication is NOT used in preventing exercise induced bronchospasm? a. Cromolyn b. Albuterol c. Theophylline d. Montelukast

More information

Annotated from the NAEPP/NHLBI Updated Asthma Guidelines and Developed Through Expert Consensus

Annotated from the NAEPP/NHLBI Updated Asthma Guidelines and Developed Through Expert Consensus Asthma Pocket Guide for Primary Care Annotated from the NAEPP/NHLBI Updated Asthma Guidelines and Developed Through Expert Consensus POSITION STATEMENT Despite advances in therapy, asthma remains a disease

More information

Children, Adolescents and Adult Asthma Clinical Practice Guideline

Children, Adolescents and Adult Asthma Clinical Practice Guideline Children, Adolescents and Adult Asthma Clinical Practice Guideline The following evidence-based guideline was developed to assist Primary Care physicians and other clinicians in the management of asthma

More information

Training Manual & Speaker s Guide

Training Manual & Speaker s Guide Training Manual & Speaker s Guide Based on National Asthma Education and Prevention Program (NAEPP) Guidelines including the NAEPP s Guidelines Implementation Panel (GIP) Priority Messages. Funded in part

More information

ACAAI Instant Reference Guide for Health Professionals

ACAAI Instant Reference Guide for Health Professionals ACAAI Instant Reference Guide for Health Professionals Guidelines for the Diagnosis and Management of Asthma Summary of Expert Panel Report 3 National Heart, Lung and Blood Institute (NHLBI) National Asthma

More information

December 6, 2010 Pediatric Severe Asthma

December 6, 2010 Pediatric Severe Asthma December 6, 2010 Pediatric Severe Asthma Lanny J. Rosenwasser, M.D. Dee Lyons/Missouri Endowed Chair in Immunology Research Professor of Pediatrics Allergy-Immunology Division Childrens Mercy Hospital

More information

NIH Asthma Guidelines. Versus. Asthma: Cost Beyond Non-Compliance

NIH Asthma Guidelines. Versus. Asthma: Cost Beyond Non-Compliance Asthma: Cost Beyond Non-Compliance WILLIAM CRAWFORD, MD OCTOBER 24, 2014 Outpatient Management of Asthma NIH Asthma Guidelines-Based Care Stepping Up Controller Therapy Newer Treatments for Severe Asthma

More information

Michael Baxley, MD, MS, MPH Chief Medical Officer Senior Marketing Medical Executive Cigna South Florida Sunrise, FL. Objectives

Michael Baxley, MD, MS, MPH Chief Medical Officer Senior Marketing Medical Executive Cigna South Florida Sunrise, FL. Objectives Michael Baxley, MD, MS, MPH Chief Medical Officer Senior Marketing Medical Executive Cigna South Florida Sunrise, FL Objectives Assess the burden and impact of asthma in the US Identify the updated 2007

More information

Objective: To correctly identify children with asthma early, and begin management that allows full activity and prevents severe exacerbations.

Objective: To correctly identify children with asthma early, and begin management that allows full activity and prevents severe exacerbations. Asthma Diagnosis and Preventive Management in Children Originally Approved: March 2014 Last Updated: March 2014 Topic Owner: Cathy Pew MD (cpew@uw.edu) Guidelines Reviewed: 1. NHLBI 2007 Expert Panel Report

More information

GINA At-A-Glance Asthma Management Reference

GINA At-A-Glance Asthma Management Reference GINA At-A-Glance Asthma Management Reference Updated 2014 Please refer to the Global Strategy for Asthma Management and Prevention (updated 2014) - www.ginasthma.org Global Initiative for Asthma DEFINITION

More information

ESSENTIALS FOR MANAGING ASTHMA

ESSENTIALS FOR MANAGING ASTHMA ESSENTIALS FOR MANAGING ASTHMA Goals of Therapy Prevent chronic and troublesome symptoms (e.g., coughing or breathlessness in the night, in the early morning, or after exertion). Maintain (near) "normal"

More information

Adult Asthma Clincial Practice Guideline Summary

Adult Asthma Clincial Practice Guideline Summary Adult Asthma Clincial Practice Guideline Summary The following evidence-based guideline was developed to assist Primary Care physicians and other clinicians in the management of asthma in adults. It was

More information

Asthma Clinical Guidelines

Asthma Clinical Guidelines Asthma Clinical Guidelines Adapted from the National Heart, Lung, and Blood Institute s (NHLBI) National Asthma Education and Prevention Program (NAEPP) 2007 Expert Panel Report 3: Guidelines for the Diagnosis

More information

AETNA BETTER HEALTH OF MISSOURI Asthma and Pregnancy practice guidelines

AETNA BETTER HEALTH OF MISSOURI Asthma and Pregnancy practice guidelines AETNA BETTER HEALTH OF MISSOURI Asthma and Pregnancy practice guidelines The Guideline was adapted from the American College of Obstetricians and Gynecologists (ACOG) to provide treatment guidance to primary

More information

Asthma Action Plans and Management of Asthma Yellow Zone Symptoms. October 2, 2015 Mary O Connor, D.O.

Asthma Action Plans and Management of Asthma Yellow Zone Symptoms. October 2, 2015 Mary O Connor, D.O. Asthma Action Plans and Management of Asthma Yellow Zone Symptoms October 2, 2015 Mary O Connor, D.O. Disclaimers I have no sponsors, grants, or affiliations to disclose. I am in private practice but I

More information

Objectives. Internal Medicine Board Review Asthma. Emily DiMango, MD. Asthma Is Prevalent: Significant Morbidity and Mortality

Objectives. Internal Medicine Board Review Asthma. Emily DiMango, MD. Asthma Is Prevalent: Significant Morbidity and Mortality Internal Medicine Board Review Asthma Emily DiMango, MD Director John Edsall/John Wood Asthma Center Columbia University Medical Center Objectives Review asthma epidemiology Asthma pathophysiology/definition

More information

ASTHMA NHLBI GUIDELINES. Today s Topics

ASTHMA NHLBI GUIDELINES. Today s Topics ASTHMA NHLBI GUIDELINES Stephen Kurachek, MD CRCCS Children s Hospitals and Clinics of Minnesota Gillette Children s Specialty Hospital CentraCare Health System Essentia Health Today s Topics NHLBI Guidelines

More information

Asthma Guidelines: Stepwise Approach to Managing Asthma

Asthma Guidelines: Stepwise Approach to Managing Asthma Asthma Guidelines: Stepwise Approach to Managing Asthma Karen Meyerson, MSN, RN, FNP-C, AE-C Asthma Network of West Michigan April 21, 2009 Acknowledgements: LeRoy M. Graham, MD, Atlanta, GA Allan T. Luskin,

More information

Clinical Practice Guideline for the Management of Asthma in Children and Adults

Clinical Practice Guideline for the Management of Asthma in Children and Adults Clinical Practice Guideline for the Management of Asthma in Children and Adults Assessment: A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function

More information

Asthma Guideline and Therapy: Simplified

Asthma Guideline and Therapy: Simplified Asthma Guideline and Therapy: Simplified DONNA J. LEE, MD PEDIATRIC PULMONOLOGY THE JOSEPH M. SANZARI CHILDREN S HOSPITAL HACKENSACK UNIVERSITY MEDICAL CENTER National Asthma Education Prevention Program-

More information

Objectives. Asthma Management

Objectives. Asthma Management Objectives Asthma Management BREATHE Conference Allergy and Asthma Specialists PC Christine Malloy MD March 22, 2013 Review the role of inflammation in asthma Discuss the components of the EPR-3 management

More information

Sheri Stensland, PharmD, AE-C, FAPhA Associate Professor of Pharmacy Practice Midwestern University/Walgreens

Sheri Stensland, PharmD, AE-C, FAPhA Associate Professor of Pharmacy Practice Midwestern University/Walgreens Sheri Stensland, PharmD, AE-C, FAPhA Associate Professor of Pharmacy Practice Midwestern University/Walgreens Sheri Stensland declares no conflicts of interest, real or apparent, and no financial interests

More information

Pediatric Asthma Updates

Pediatric Asthma Updates Pediatric Asthma Updates Kenan Haver, M.D. Division of Respiratory Diseases Director, Pulmonary Division Asthma Center Boston Children s Hospital International Disclosures I have none relevant to this

More information

Category Purpose Medication types

Category Purpose Medication types 1 of 7 2/21/2011 7:34 PM By Mayo Clinic staff Asthma medications play an important role in managing signs and symptoms such as coughing, wheezing and shortness of breath. Long-term control medications

More information

Lessons Learned from the Severe Asthma Program

Lessons Learned from the Severe Asthma Program Lessons Learned from the Severe Asthma Program March 20, 2015 Jonathan Gaffin, MD, MMSc Division of Respiratory Diseases Boston Children s Hospital Sachin Baxi, MD Division of Allergy & Immunology Boston

More information

Available Strengths. Formulary Limits. Single Agents

Available Strengths. Formulary Limits. Single Agents MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Asthma/COPD P&T DATE 9/23/2015 CLASS: Respiratory Disorders REVIEW HISTORY 5/15, 9/14, 2/13, 5/12 LOB: Medi-Cal, SJHA (MONTH/YEAR)

More information

STANFORD COORDINATED CARE ASTHMA MANAGEMENT PROTOCOL MEDICATION THERAPY MANAGEMENT SERVICES

STANFORD COORDINATED CARE ASTHMA MANAGEMENT PROTOCOL MEDICATION THERAPY MANAGEMENT SERVICES STANFORD COORDINATED CARE ASTHMA MANAGEMENT PROTOCOL MEDICATION THERAPY MANAGEMENT SERVICES Related Documents: Asthma Planned Visit Protocol for Care Coordinators Asthma Action Plan (English and Spanish)

More information

Adult asthma management: focus on control

Adult asthma management: focus on control Adult asthma management: focus on control Jennifer W. McCallister, MD Associate Professor Pulmonary, Allergy, Critical Care & Sleep Medicine The Ohio State University Wexner Medical Center Objectives Apply

More information

The Asthma Guidelines: Ambulatory Management of Asthma

The Asthma Guidelines: Ambulatory Management of Asthma The Asthma Guidelines: Ambulatory Management of Asthma Christopher H. Fanta, M.D. Partners Asthma Center Brigham and Women s Hospital Harvard Medical School Objectives Review the medications available

More information

Spirometry Workshop for Primary Care Nurse Practitioners

Spirometry Workshop for Primary Care Nurse Practitioners Spirometry Workshop for Primary Care Nurse Practitioners Catherine Casey S. Jones PhD, RN, AE-C, ANP-C Certified Adult Nurse Practitioner Texas Pulmonary & Critical Care Consultants P.A. and Visiting Assistant

More information

CARE GUIDE for ASTHMA

CARE GUIDE for ASTHMA Suggested Diagnosis (1) Confirm a diagnosis by establishing that: Episodic symptoms of airflow obstruction or airway hyperresponsiveness are present Airflow obstruction is at least partially reversible

More information

ASTHMA MEDICATION RATIO

ASTHMA MEDICATION RATIO ASTHMA MEDICATION RATIO APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD OF CARE RECOMMENDED CODES DOCUMENTATION REQUIREMENTS What documentation HEDIS

More information

Asthma Management in Adults

Asthma Management in Adults Asthma Management in Adults Medical Care Program, Southern California CLINICAL PRACTICE GUIDELINES The following evidence-based guideline was developed to assist Primary Care physicians and other clinicians

More information

PacifiCare Health Plans Asthma Practice Guidelines Outpatient Management of Asthma. At each regular or unplanned visit, assess:

PacifiCare Health Plans Asthma Practice Guidelines Outpatient Management of Asthma. At each regular or unplanned visit, assess: Assessment Frequency of visits PacifiCare Health Plans Asthma Practice Guidelines Outpatient Management of Asthma Schedule regular visits, every 1-6 months. At each regular or unplanned visit, assess:

More information

Diagnosis, Treatment and Management of Asthma

Diagnosis, Treatment and Management of Asthma Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.

More information

Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma

Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma Important Complete asthma control needs to be achieved for at least 12 weeks before attempting

More information

TOP PERFORMANCE OF ATHLETES WITH ASTHMA. Nicolette Myers, MD Pulmonary/Critical Care/Sleep Medicine Park Nicollet Clinic June 5, 2015

TOP PERFORMANCE OF ATHLETES WITH ASTHMA. Nicolette Myers, MD Pulmonary/Critical Care/Sleep Medicine Park Nicollet Clinic June 5, 2015 TOP PERFORMANCE OF ATHLETES WITH ASTHMA Nicolette Myers, MD Pulmonary/Critical Care/Sleep Medicine Park Nicollet Clinic June 5, 2015 DISCLOSURE INFORMATION TRIA ORTHOPEDICS AND SPORTS MEDICINE CONFERENCE

More information

Chronic asthma: management

Chronic asthma: management Chronic asthma: management NICE guideline: short version Draft for consultation, December 0 This guideline covers managing chronic asthma in adults, young people and children. It aims to improve asthma

More information

ASTHMA TREATMENT GUIDELINES

ASTHMA TREATMENT GUIDELINES ASTHMA TREATMENT GUIDELINES Definition: Asthma is a chronic inflammatory respiratory disease. It can affect people of any age, but often starts in childhood. It is characterised by attacks (also known

More information

Glucocorticoids, Inhaled Therapeutic Class Review (TCR) February 7, 2012

Glucocorticoids, Inhaled Therapeutic Class Review (TCR) February 7, 2012 Glucocorticoids, Inhaled Therapeutic Class Review (TCR) February 7, 2012 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying,

More information

Glucocorticoids, Inhaled Therapeutic Class Review (TCR)

Glucocorticoids, Inhaled Therapeutic Class Review (TCR) Glucocorticoids, Inhaled Therapeutic Class Review (TCR) July 31, 2015 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying,

More information

Asthma Prescribing Guidelines Adults and Children over 12 years

Asthma Prescribing Guidelines Adults and Children over 12 years South Staffordshire Area Prescribing Group Asthma Prescribing Guidelines Adults and Children over 12 years Inhaler choices in this guideline are different from previous versions produced by the APG. It

More information

The Management of Asthma in Special Populations

The Management of Asthma in Special Populations The Management of Asthma in Special Populations Scott K. Stolte, Pharm.D. Associate Professor and Chair Department of Pharmacy Practice Bernard J. Dunn School of Pharmacy Shenandoah University Objectives

More information

Leukotriene receptor antagonists: Montelukast and zafirlukast

Leukotriene receptor antagonists: Montelukast and zafirlukast Bulletin 61 February 2014 2.0 Leukotriene receptor antagonists: Montelukast and zafirlukast Across the PrescQIPP membership (20.2 million patients, November 2013), annual spend for the leukotriene receptor

More information

Cough-variant Asthma. Pramod Kelkar, MD Founder, National Cough Clinic

Cough-variant Asthma. Pramod Kelkar, MD Founder, National Cough Clinic Cough-variant Asthma Pramod Kelkar, MD Founder, National Cough Clinic www.allergy-care.net www.nationalcoughclinic.com Private Practice Minneapolis, MN, USA 1 Disclosures Speakers Bureau MERCK, Astra-Zeneca,

More information

Management of Asthma

Management of Asthma Federal Bureau of Prisons Clinical Practice Guidelines May 2013 Clinical guidelines are made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant

More information

MEDICAL POLICY STATEMENT

MEDICAL POLICY STATEMENT MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 06/15/2011 02/15/2017 03/09/2016 Policy Name Policy Number Xolair/Nucala SRx-0013 Policy Type Medical

More information

Asthma and Wheezing in the young children. History. Asthma Lecture. History. History 8/9/2011. Jesus Ramon Guajardo

Asthma and Wheezing in the young children. History. Asthma Lecture. History. History 8/9/2011. Jesus Ramon Guajardo If it shines Is it gold? Is wheezing = asthma? Seems that there is some magic in the asthma world You can t call it asthma until the child is 2 years of age a one year old child can t have asthma yet you

More information

Asthma. Board Review Sam Sandlin August 13, 2008

Asthma. Board Review Sam Sandlin August 13, 2008 Asthma Board Review Sam Sandlin August 13, 2008 Content Specification Know that exercise induced asthma may be a sign of poorly controlled asthma. Many patients complain only of exercise related symptoms

More information

Chronic Obstructive Pulmonary Disease (COPD) Clinician Guide AUGUST 2016

Chronic Obstructive Pulmonary Disease (COPD) Clinician Guide AUGUST 2016 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Chronic Obstructive Pulmonary Disease (COPD) Clinician Guide AUGUST 2016 Introduction The 2016 KP National Chronic Obstructive Pulmonary Disease

More information

Understanding the Risks and Benefits of Stepping Down Asthma MedicaDons

Understanding the Risks and Benefits of Stepping Down Asthma MedicaDons Understanding the Risks and Benefits of Stepping Down Asthma MedicaDons 4813 Workshop: Stepping Down Asthma MedicaDons: Benefits and Risks Monday March 3, 2014 4:45 pm to 6:00 pm AAAAI 2014 John B. Hagan,

More information

It doesn t work if it doesn t get into your Lungs! Aimee Tiller, RN, AE-C Asthma Nurse Coordinator Pediatric Pulmonology, MUSC

It doesn t work if it doesn t get into your Lungs! Aimee Tiller, RN, AE-C Asthma Nurse Coordinator Pediatric Pulmonology, MUSC It doesn t work if it doesn t get into your Lungs! Aimee Tiller, RN, AE-C Asthma Nurse Coordinator Pediatric Pulmonology, MUSC Short acting beta agonists (SABAs) - quick relief - relieves acute bronchospasm

More information

Chapter 12 Nonsteroidal Antiasthma Agents Study Guide and Application Exercise

Chapter 12 Nonsteroidal Antiasthma Agents Study Guide and Application Exercise Chapter 12 Nonsteroidal Antiasthma Agents Study Guide and Application Exercise 1. Read chapter 2. Review objectives (p.202) 3. Review key terms and definitions (p.202) Add Airway remodeling. 4. What are

More information

Management of Asthma in School- Aged Children and Adolescents

Management of Asthma in School- Aged Children and Adolescents Management of Asthma in School- Aged Children and Adolescents Sandy Durrani, MD Abstract Asthma is one of the most common childhood diseases in the world and a significant cause of morbidity and health

More information

Asthma Pharmacotherapy: Stepwise Approach to Managing Asthma

Asthma Pharmacotherapy: Stepwise Approach to Managing Asthma Asthma Pharmacotherapy: Stepwise Approach to Managing Asthma Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) Karen Meyerson, MSN, APRN, NP-C, AE-C Director, Commercial Care Management

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version

More information

Differentiating Asthma from COPD: Role of History, Physical Examination, Laboratory Studies, and Lung Function Testing

Differentiating Asthma from COPD: Role of History, Physical Examination, Laboratory Studies, and Lung Function Testing Differentiating Asthma from COPD: Role of History, Physical Examination, Laboratory Studies, and Lung Function Testing Stephen P Peters, MD, PhD, FAAAAI Professor of Medicine, Pediatrics and Translational

More information

PEDIATRIC ASTHMA SPEAKER S KIT / Pharmacologic Management

PEDIATRIC ASTHMA SPEAKER S KIT / Pharmacologic Management PEDIATRIC ASTHMA SPEAKER S KIT / Pharmacologic Management P H A R M A C O L O G I C M A N A G E M E N T O F A S T H M A / S L I D E 1 1 G O A L S O F T H E R A P Y F O R T H E C H I L D / S L I D E 2 PEDIATRIC

More information

Asthma Diagnosis and Treatment Guideline

Asthma Diagnosis and Treatment Guideline Asthma Diagnosis and Treatment Guideline Definition... 2 Diagnosis... 2 Classify Severity... 2 Table 1. Classifying asthma severity in patients not currently taking medications... 3 Assess Control... 4

More information

The National Asthma Education. Overview of Changes to Asthma Guidelines: Diagnosis and Screening

The National Asthma Education. Overview of Changes to Asthma Guidelines: Diagnosis and Screening Overview of Changes to Asthma Guidelines: Diagnosis and Screening SUSAN M. POLLART, MD, MS, and KURTIS S. ELWARD, MD, MPH Department of Family Medicine, University of Virginia School of Medicine, Charlottesville,

More information

Clinical Practice Guideline: Asthma

Clinical Practice Guideline: Asthma Clinical Practice Guideline: Asthma INTRODUCTION A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function both before and after bronchodilator

More information

ADULT ASTHMA MANAGEMENT February 2011

ADULT ASTHMA MANAGEMENT February 2011 Chicago, Illinois PAGE: 1 of 30 ADULT ASTHMA MANAGEMENT February 2011 Key Content Expert: Sharmilee Nyenhuis, MD- Chair, Adult Asthma Team, Nikki Garg, MD, Susan Corbridge, PhD, APN, and Lori Wilken, PharmD

More information

Asthma and the School Nurse

Asthma and the School Nurse Asthma and the School Nurse University of Vermont Medical Center Vermont Children s Hospital Children s Specialty Center Julie Hounchell MSN, FNP-BC Pediatric Pulmonology Objectives Discuss Pathophysiology

More information

Care for children with asthma is optimized when pharmacists

Care for children with asthma is optimized when pharmacists P R A C T I C E G U I D E L I N E S Elaine Lau, BScPhm, PharmD, MSc Pharmacist-specific summary of pediatric asthma guidelines Care for children with asthma is optimized when pharmacists actively collaborate

More information

Asthma & COPD: Asthma and chronic obstructive pulmonary disease. Clearing the Air. John s case. Pathophysiology

Asthma & COPD: Asthma and chronic obstructive pulmonary disease. Clearing the Air. John s case. Pathophysiology Asthma & COPD: Clearing the Air Alan Kaplan, MD, CCFP(EM) As presented at Primary Care Today, Toronto (May 5, 2005). Asthma and chronic obstructive pulmonary disease (COPD) are the two most common obstructive

More information

At-A-Glance Outpatient Management Reference for Chronic Obstructive Pulmonary Disease (COPD)

At-A-Glance Outpatient Management Reference for Chronic Obstructive Pulmonary Disease (COPD) At-A-Glance Outpatient Management Reference for Chronic Obstructive Pulmonary Disease (COPD) BASED ON THE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT AND PREVENTION OF COPD GLOBAL INITIATIVE FOR CHRONIC

More information

5. Treatment of childhood asthma

5. Treatment of childhood asthma 5. Treatment of childhood asthma 5.1 Maintenance therapy 5.1.1 rugs Inhaled glucocorticoids (IG). In children older than 3 years old, the efficacy of IGs is well established, and are considered the first-line

More information

Outpatient Guideline for the Diagnosis and Management of Asthma

Outpatient Guideline for the Diagnosis and Management of Asthma Outpatient Guideline for the Diagnosis and Management of Asthma Initial Visit Follow-Up Visits See page 2 Asthma Diagnosis See page 3 Classifying Asthma Severity and Initiating Treatment See pages 2 and

More information

A. Chronic inflammation from repeated exposure to noxious particles and gases

A. Chronic inflammation from repeated exposure to noxious particles and gases CHAPTER 15. CHRONIC OBSTRUCTIVE PULMONARY DISEASE SELF-ASSESSMENT QUESTIONS 1. All of the following play a role in the pathophysiology of COPD except: A. Chronic inflammation from repeated exposure to

More information

Originally Published: ican Physician News and Views Spring 2007 Newsletter. ican Website Physician Newsletter Article Archive Page 1

Originally Published: ican Physician News and Views Spring 2007 Newsletter. ican Website Physician Newsletter Article Archive Page 1 ALVESCO: NEW ICS CICLESONIDE by Dr. Sheldon Spier Until recently there have been 3 excellent inhaled corticosteroids (ICS) in primary use for asthma in Canada budesonide (Pulmicort), beclomethasone (Qvar)

More information

Clinical Problem and Management Issues

Clinical Problem and Management Issues Guidelines for Clinical Care Inpatient Asthma Guideline Team Team Leader Sean K Kesterson, MD General Medicine Team Members Joyce E Kaferle, MD Family Medicine Jill A Noble, MD General Pediatrics Manuel

More information

SPRINGFIELD CLINIC ASTHMA EDUCATION

SPRINGFIELD CLINIC ASTHMA EDUCATION SPRINGFIELD CLINIC ASTHMA EDUCATION Table of Contents 1. What is Asthma? 2. Asthma Triggers 3. Using Your Inhaler 4. Cleansing Practices for Inhaled Medication 5. Controlling Your Asthma 6. Fast Acting

More information

Medication Management for People with Asthma

Medication Management for People with Asthma Medication Management f People with Asthma BCBS ACO Measure Medication Management f People with Asthma Click here to go to Table of Contents BCBS Measure: Page 214 of 234 Dated: 5/27/2015 2015 BCBS ACO

More information

Mepolizumab (Nucala ) for Treatment of Severe Asthma with Eosinophilic Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks

Mepolizumab (Nucala ) for Treatment of Severe Asthma with Eosinophilic Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks Mepolizumab (Nucala ) for Treatment of Severe Asthma with Eosinophilic Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 18, 2015 Background: The

More information

Drugs Used to Treat Asthma

Drugs Used to Treat Asthma Drugs Used to Treat Asthma Asthma: is an inflammatory disease of the airways characterized by episodes of acute bronchoconstriction causing shortness of breath, cough, chest tightness, wheezing, and rapid

More information

Continuing Professional Pharmacy Development (CPPD) CPPD calendar. Facebook: QUCPPD

Continuing Professional Pharmacy Development (CPPD) CPPD calendar. Facebook: QUCPPD Continuing Professional Pharmacy Development (CPPD) CPPD 2013-2014 calendar Facebook: QUCPPD Continuing Professional Pharmacy Development (CPPD) Essentials in Asthma Management: The Action Plan 30 Oct

More information

Indiana Medicaid Drug Utilization Review Board Newsletter

Indiana Medicaid Drug Utilization Review Board Newsletter Indiana Medicaid Drug Utilization Review Board Newsletter Indiana Medicaid DUR Board Room W382 Indiana State Government Center, South 402 West Washington Street Indianapolis, Indiana 46204 DUR Board Members

More information